Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020)

References

• Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Design. 2007;13(3):333–346.
   PubMed Web of Science ®Google Scholar
• Dove A. MMP inhibitors: glimmers of hope amidst clinical failures. Nat Med. 2002;8(2):95.
   PubMed Web of Science ®Google Scholar
• Beckett RP, Whittaker M. Matrix metalloproteinase inhibitors 1998. Exp Opin Ther Patents. 1998;8(3):259–282.
   Web of Science ®Google Scholar
• Li N-G, Tang Y-P, Duan J-A, et al. Matrix metalloproteinase inhibitors: a patent review (2011 – 2013). Exp Opin Ther Patents. 2004;24(9):1039–1052.
   Google Scholar
• Hu J, Van den Steen PE, Sang Q-XA, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6:480–498.
   PubMed Web of Science ®Google Scholar
• Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008;29(5):290–308.
   PubMed Web of Science ®Google Scholar
• Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol. 2013;13(9):649–665.
   PubMed Web of Science ®Google Scholar
• Fields GB. The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma. Cells. 2019;8(9):984.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke RC, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014;13:904–927.
   PubMed Web of Science ®Google Scholar
• Rudek MA, Venitz J, Figg WD. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy. 2002;22(6):705–720.
   PubMed Web of Science ®Google Scholar
• Puerta DT, Cohen SM. A bioinorganic perspective on matrix metalloproteinase inhibition. Curr Top Med Chem. 2004;4(15):1551–1573.
   PubMed Web of Science ®Google Scholar
• Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1–73.
   PubMed Web of Science ®Google Scholar
• Fabre B, Ramos A, de Pascual-teresa B. Targeting matrix metalloproteinases: exploring the dynamics of the S1′ pocket in the design of selective, small molecule inhibitors. J. Med Chem. 2014;57(24):10205–10219.
   Web of Science ®Google Scholar
• Devy L, Dransfield DT. New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem Res Int. 2011;80(4):191670.
   Google Scholar
• Nguyen TT, Ding D, Wolter WR, et al. Validation of matrix metalloproteinase-9 (MMP-9) as a novel target for treatment of diabetic foot ulcers in humans and discovery of a potent and selective small-molecule MMP-9 inhibitor that accelerates healing. J Med Chem. 2018;61(19):8825–8837.
   PubMed Web of Science ®Google Scholar
• Amar S, Fields GB. Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445–447.
   PubMed Web of Science ®Google Scholar
• Boelen GJ, Boute L, d’Hoop J, et al. Matrix metalloproteinases and inhibitors in dentistry. Clin Oral Investig. 2019;23(7):2823–2835.
   PubMed Web of Science ®Google Scholar
• Fields GB. Mechanisms of action of novel drugs targeting angiogenesis-promoting matrix metalloproteinases. Front Immun. 2019;10:1278.
   PubMed Web of Science ®Google Scholar
• Lia N-G, Shib Z-H, Tang Y-P, et al. Selective matrix metallo proteinase inhibitors for cancer. Curr Med Chem. 2009;16(29):3805–3827.
   PubMed Web of Science ®Google Scholar
• Tauro M, McGuire J, Lynch CC. New approaches to selectively target cancer-associated matrix metalloproteinase activity. Cancer Metastasis Rev. 2014;33(4):1043–1057.
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol. 2001;15(5):805–829.
   PubMed Web of Science ®Google Scholar
• Chopra S, Overall CM, Dufour A. Matrix metalloproteinases in the CNS: interferons get nervous. Cell Mol Life Sci. 2019;76(16):3083–3095.
   PubMed Web of Science ®Google Scholar
• Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26(5A):3579–3583.
   PubMed Web of Science ®Google Scholar
• Rangasamy L, Di Geronimo B, Ortín I, et al. Molecular imaging probes based on matrix metalloproteinase inhibitors (MMPIs). Molecules. 2019;24(16):2982.
   Web of Science ®Google Scholar
• Ala-aho R, Kähäri V-M. Collagenases in cancer. Biochimie. 2005;87(3–4):273–286.
   PubMed Web of Science ®Google Scholar
• Amar S, Smith L, Fields GB. Matrix metalloproteinase collagenolysis in health and disease. Biochim Biophys Acta Mol Cell Res. 2017;1864(11):1940–1951.
   PubMed Web of Science ®Google Scholar
• Knäuper V, López-Otín C, Smith B, et al. Biochemical characterization of human collagenase-3. J Biol Chem. 1996;271(3):1544–1550.
   PubMed Web of Science ®Google Scholar
• Deng SJ, Bickett DM, Mitchell JL, et al. Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library. J Biol Chem. 2000;275(40):31422–31427.
   PubMed Web of Science ®Google Scholar
• Inada M, Wang Y, Byrne MH, et al. Critical roles for collagenase-3 (MMP13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA. 2004;101(49):17192–17197. .
   PubMed Web of Science ®Google Scholar
• Alipour H, Raz A, Zakeri S, et al. Therapeutic applications of collagenase (metalloproteases): a review, asian pac j trop biomed. 2016;6(11):975–981.
   Google Scholar
• Morrison C, Overall C. Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis. J Biol Chem. 2011;286:34271–34285.
   PubMed Web of Science ®Google Scholar
• Nara H, Kori M. Discovery of novel, highly potent and selective matrix metalloproteinase (MMP-13) inhibitors with a 1,2,4-triazol-3-yl moiety as a zinc binding group using a structure-based design approach. J Med Chem. 2017;60:608–626.
   PubMed Web of Science ®Google Scholar
• Lia N-G, Shib Z-H, Tang Y-P, et al. New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158). Expert Opin Ther Pat. 2013;23(5):669–675.
   PubMed Web of Science ®Google Scholar
• Nara H, Sato K, Kaieda A, et al. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. Bioorg Med Chem. 2016;24(23):6149–6165.
   PubMed Web of Science ®Google Scholar
• Florida Atlantic University Board of Trustees. Selective matrix metalloproteinase-13 inhibitors. WO2018226837 (2018)
   Google Scholar
• Lauer-Fields JL, Fields GB. Triple-helical peptide analysis of collagenolytic protease activity. Biol Chem. 2002;383(7–8):1095–1105.
   PubMed Web of Science ®Google Scholar
• Lauer-Fields JL, Broder T, Sritharan T, et al. Kinetic analysis of matrix metalloproteinase activity using fluorogenic triple-helical substrates. Biochemistry. 2001;40(19):5795–5803.
   PubMed Web of Science ®Google Scholar
• Takaishi H, Kimura T, Dalal S, et al. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol. 2008;9(1):47–54.
   PubMed Web of Science ®Google Scholar
• Neuhold LA, Killar L, Zhao WG, et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest. 2001;107(1):35–44.
   PubMed Web of Science ®Google Scholar
• Roth J, Minond D, Darout E, et al. Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett. 2011;21(23):7180–7184.
   PubMed Web of Science ®Google Scholar
• Spicer TP, Jiang J, Taylor AB, et al. Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. J Med Chem. 2014;57(22):9598–9611.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals A, Inc. matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases. WO2014062204 (2014)
   Google Scholar
• Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheumatol. 2009;60(7):2008–2018.
   PubMed Web of Science ®Google Scholar
• Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. BBA Rev Cancer. 2012;1825(1):29–36.
   Web of Science ®Google Scholar
• Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 2005;5(3):203–220.
   PubMed Web of Science ®Google Scholar
• Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Tar. 2003;7(3):385–397.
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–410.
   PubMed Web of Science ®Google Scholar
• Mu D, Cambier S, Fjellbirkeland L, et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol. 2002;157(3):493–507.
   PubMed Web of Science ®Google Scholar
• Bergers G, Brekken R, Mcmahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737–744.
   PubMed Web of Science ®Google Scholar
• Chetty C, Lakka SS, Bhoopathi P, et al. Alters VEGF expression via αvβ3 integrin-mediated pi3k/akt signaling in a549 lung cancer cells. Int J Cancer. 2010;127(5):1081–1095.
   PubMed Web of Science ®Google Scholar
• Dufour A, Zucker S, Sampson NS, et al. Role of matrix metalloproteinase-9 dimers in cell migration. J Biol Chem. 2010;285(46):35944–35956.
   PubMed Web of Science ®Google Scholar
• Higashi S, Miyazaki K. Identification of amino acid residues of the matrix metalloproteinase-2 essential for its selective inhibition by beta-amyloid precursor protein-derived inhibitor. Biol Chem. 2008;283(15):10068–10078.
   Web of Science ®Google Scholar
• Roomi MW, Monterrey JC, Kalinovsky T, et al. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009;21(5):1323–1333.
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9–34.
   PubMed Web of Science ®Google Scholar
• Xun L. Gelatinase inhibitors: a patent review (2011-2017). Expert Opin Ther Patents. 2018;28(1):31–46.
   PubMed Web of Science ®Google Scholar
• Adhikari N, Amin SA, Jha T. Collagenases and gelatinases and their inhibitors as anticancer agents. In: Gupta SP, editor. Cancer-leading proteases: structures, functions, and inhibition. New York, NY, USA: Elsevier; 2020. p. 265–294.
   Google Scholar
• Beutel B, Song J, Konken CP, et al. New in vivo compatible matrix metalloproteinase (MMP)-2 and MMP-9 Inhibitors. Bioconjug Chem. 2018;29(11):3715–3725.
   PubMed Web of Science ®Google Scholar
• Lenci E, Contini A, Trabocchi A. Discovery of a D-pro-lys peptidomimetic inhibitor of MMP9: addressing the gelatinase selectivity beyond S1′ subsite. Bioorg Med Chem Lett. 2020;30(20):127467.
   PubMed Web of Science ®Google Scholar
• Lenci E, Innocenti R, Di Francescantonio T, et al. Identification of highly potent and selective MMP2 inhibitors addressing the S1′ subsite with D-proline-based compounds. Bioorg Med Chem. 2019;27(9):1891–1902.
   PubMed Web of Science ®Google Scholar
• Mangiatordi GF, Guzzo T, Rossano EC, et al. Design, synthesis, and biological evaluation of tetrahydro-β-carboline derivatives as selective sub-nanomolar gelatinase inhibitors. ChemMedChem. 2018;13(13):1343–1352.
   PubMed Web of Science ®Google Scholar
• Rempe RG, Hartz AM, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab. 2016;36(9):1481–1507.
   PubMed Web of Science ®Google Scholar
• Brkic M, Balusu S, Libert C, et al. Friends or foes: matrix metalloproteinases and their multifaceted roles. Mediators Inflamm. 2015;2015:620581
   PubMed Web of Science ®Google Scholar
• The Research Foundation for the State University of New York. matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same. WO2018175670; 2018.
   Google Scholar
• Alford VM, Kamath A, Ren X, et al. Targeting the hemopexin-like domain of latent matrix metalloproteinase-9 (prommp-9) with a small molecule inhibitor prevents the formation of focal adhesion junctions. ACS Chem Biol. 2017;12(11):2788–2803.
   PubMed Web of Science ®Google Scholar
• Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci. 2005;6(12):931–944.
   PubMed Web of Science ®Google Scholar
• Nagy V. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci. 2006;26(7):1923–1934.
   PubMed Web of Science ®Google Scholar
• Konopka A, Grajkowska W, Ziemiańska K, et al. Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia. Epilepsy Res. 2013;1(1–2):45–58.
   Google Scholar
• Yamamori H, Hashimoto R, Ishima T, et al. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett. 2013;556:37–41.
   PubMed Web of Science ®Google Scholar
• Fragkouli A, Papatheodoropoulos C, Georgopoulos S, et al. Enhanced neuronal plasticity and elevated endogenous sAPPα levels in mice over‐expressing MMP9. J Neurochem. 2012;121(2):239–251.
   PubMed Web of Science ®Google Scholar
• Zipfel P, Rochais C, Baranger K, et al. Matrix metalloproteinases as new targets in alzheimer’s disease: opportunities and challenges. J Med Chem. 2020;63(19):10705–10725.
   PubMed Web of Science ®Google Scholar
• Bienkowski P, Samochowiec J, Pelka-Wysiecka J, et al. Functional polymorphism of matrix metalloproteinase-9 (MMP9). Pharmacol Rep. 2015;67(3):442–445.
   PubMed Web of Science ®Google Scholar
• Iproteos SL Gelatinase inhibitors and use thereof. WO2017085034 (2017)
   Google Scholar
• Bertran A, Khomiak D, Konopka A, et al. Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors. Bioorg Chem. 2020;94:103365.
   PubMed Web of Science ®Google Scholar
• Bartolome RA, Ferreiro S, Miquilena-Colina ME, et al. The chemokine receptor cxcr4 and the metalloproteinase mt1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol. 2009;174(2):602–612.
   PubMed Web of Science ®Google Scholar
• Lakhan SE, Kirchgessner A, Tepper D, et al. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol. 2013;4:32.
   PubMed Web of Science ®Google Scholar
• University of Notre Dame Du Lac. Selective matrix metalloproteinase inhibitors. WO2015127302 (2015)
   Google Scholar
• Jones JI, Nguyen TT, Peng Z, et al. Targeting MMP-9 in diabetic foot ulcers. Pharmaceuticals. 2019;12(2):79.
   Web of Science ®Google Scholar
• Mallinckrodt LLC Matrix metalloproteinase (MMP) targeted agents for imaging and therapy. WO2014151988 (2014)
   Google Scholar
• Freskos JN, Asmelash B, Gaston KR, et al. Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes. Bioorg Med Chem Lett. 2013;23(20):5566–5570.
   PubMed Web of Science ®Google Scholar
• Remacle AG, Shiryaev SA, Golubkov VS, et al. Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells. J Biol Chem. 2013;288(28):20568–20580.
   PubMed Web of Science ®Google Scholar
• Loyola University of Chicago. Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy. WO2020006384 (2020)
   Google Scholar
• Lutz MR, Flieger S, Colorina A, et al. Carborane‐containing matrix metalloprotease (MMP) ligands as candidates for boron neutron‐capture therapy (BNCT). ChemMedChem. 2020;15(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Valliant J, KJ G, AS K, et al. The medicinal chemistry of carboranes. Coord Chem. 2002;232(1–2):173–230.
   Google Scholar
• Trivillin VA, Bruno LJ, Gatti DA, et al. Boron neutron capture synovectomy (BNCS) as a potential therapy for rheumatoid arthritis: radiobiological studies at RA-1 nuclear reactor in a model of antigen-induced arthritis in rabbits. Radiat Environ Biophys. 2016;55(4):467–475.
   PubMed Web of Science ®Google Scholar
• Yip C, Foidart P, Noël A. Sounni NE MT4-MMP: the GPI-anchored membrane-type matrix metalloprotease with multiple functions in diseases. Int J Mol Sci. 2019;20(2):354.
   Web of Science ®Google Scholar
• WR E, XS P, JM F, et al. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J Biol Chem. 2000;275(19):14046–14055.
   PubMed Web of Science ®Google Scholar
• Itoh Y, Kajita M, Kinoh H, et al. Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. J Biol Chem. 1999;274(48):34260–34266.
   PubMed Web of Science ®Google Scholar
• Centro nacional de investigaciones cardiovascular carlos iii. inhibitors of membrane-type 4 matrix metalloproteinase and its use in the treatment of diseases benefiting from an increase in the activity of patrolling monocytes. WO 2019086683 (2019)
   Google Scholar
• Lagente V, Le Quement C, Boichot E. Macrophage metalloelastase (MMP-12) as a target for inflammatory respiratory diseases. Exp Opin Ther Targets. 2009;13(3):287–295.
   PubMed Web of Science ®Google Scholar
• Demedts IK, Morel-montero A, Lebecque S, et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax. 2006;61(3):196–201.
   PubMed Web of Science ®Google Scholar
• He MK, Le Y, Zhang YF, et al. Matrix metalloproteinase 12 expression is associated with tumor FOXP3+ regulatory T cell infiltration and poor prognosis in hepatocellular carcinoma. Oncol Lett. 2018;16(1):475–482.
   PubMed Web of Science ®Google Scholar
• Churg A, Wang R, Wang X, et al. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax. 2007;62(8):706–711.
   PubMed Web of Science ®Google Scholar
• Selective NP. MMP-12 inhibitors: WO-2008057254. Exp Opin Ther Pat. 2009;19(7):1029–1034.
   PubMed Web of Science ®Google Scholar
• Foresee pharmaceuticals USA Inc. matrix metalloproteinase (MMP) Inhibitors and methods of use thereof. WO2019222157 (2019)
   Google Scholar
• DSM IP assets b.v. phosphinic peptide derivatives for use as MMP-12 inhibitors. WO2017093093 (2017)
   Google Scholar
• Commissariat a l’Energie atomique et aux energie alternatives and the university of british columbia. Inhibitors of MMP-12 as antiviral Agents. EP2907512 (2014)
   Google Scholar
• Devel L, Rogakos V, David A, et al. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J Biol Chem. 2006;281(16):11152–11160.
   PubMed Web of Science ®Google Scholar
• Centre national de la recherche scientifique – CNRS and the university de reims champagne-ardenne. Metalloproteinase inhibitors, methods for producing same, and therapeutic uses thereof. WO2015028766 (2015)
   Google Scholar
• Bayer Pharma Aktiengesellschaft. 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases. WO2015150350 (2015)
   Google Scholar
• Bayer Pharma Aktiengesellschaft. Substituted benzotriazinone butane acids and use thereof. WO2015150364 (2015)
   Google Scholar